Patent Number: 8,791,074

Title: Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors

Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.

Inventors: Leppla; Stephen (Bethesda, MD), Liu; Shi-Hui (Gaithersburg, MD), Netzel-Arnett; Sarah (Gaithersburg, MD), Birkedal-Hansen; Henning (Bethesda, MD), Bugge; Thomas (Bethesda, MD)

Assignee: The United States of America as Represented by the Secretary, Department of Health and Human Services

International Classification: A61K 38/00 (20060101)

Expiration Date: 7/29/12018